ProMetic Life Sciences Inc.

Corporate Snapshot

ProMetic Life Sciences Inc. ("ProMetic" or "the Company") is a global biopharmaceutical company offering technologies for large-scale drug purification, drug development, proteomics, clinical diagnostics, and the elimination of pathogens, as well as products to treat anemia, neutropenia, cancer, and autoimmune disease/inflammation. ProMetic uses its proprietary Affinity Technology, which employs the Company's Mimetic Ligand™ technology (highly stable chemical hooks that selectively recognize and bind to target biomolecules) to facilitate a variety of applications where a target biomolecule requires purification or removal. This technology can reduce manufacturing costs and increase the yield of existing drugs or drug candidates. The Company reorganized in 2005 and is now structured as a parent company with four separate operating units: ProMetic BioSciences Ltd (PBL [UK]), ProMetic BioTherapeutics, Inc. (PBT [U.S.]), ProMetic BioSciences Inc. (PBI [Canada]), and BSafE Innovations Inc. (Canada). The objective of this reorganization is for each unit to function independently in terms of management, funding of operations, and development of specific products and services. Based on its proprietary technologies, ProMetic has a large number of collaborations with entities that are active in the biotechnology and pharmaceutical industries. These partnerships serve to generate revenue for the Company.